Day one: The dis­rup­tor-in-chief at Bridge­Bio in­vites Brent Saun­ders on­to the board

Now that Al­ler­gan has been swept up in­to Ab­b­Vie fol­low­ing their $63 bil­lion buy­out, it’s time for ex-CEO Brent Saun­ders to kick­start the next chap­ter of his ca­reer. And his new post as an in­de­pen­dent board mem­ber at Bridge­Bio looks to be right up his al­ley.

Bridge­Bio, led by CEO Neil Ku­mar, has built up a hub-and-spoke op­er­a­tion in­volv­ing a va­ri­ety of sub­sidiaries on dif­fer­ent de­vel­op­ment paths as the McK­in­sey vet looked to cre­ate a new kind of bio­phar­ma com­pa­ny, free of the usu­al cor­po­rate clut­ter that slows the gi­ants down.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE